Adma Biologics Inc (NASDAQ:ADMA) shares, rose in value on Wednesday, March 26, with the stock price down by -2.57% to the previous day’s close as strong demand from buyers drove the stock to $19.70.
Actively observing the price movement in the last trading, the stock closed the session at $20.22, falling within a range of $19.45 and $20.25. The value of beta (5-year monthly) was 0.604 whereas the PE ratio was 24.34 over 12-month period. Referring to stock’s 52-week performance, its high was $23.64, and the low was $5.89. On the whole, ADMA has fluctuated by 27.59% over the past month.
With the market capitalization of Adma Biologics Inc currently standing at about $4.68 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 495.23M, with a low estimate of 111.9M and a high estimate of 119.1M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 116.4M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ADMA’s technical picture suggests that short-term indicators denote the stock is a 75% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0.80, with the price of ADMA currently trading nearly 8.61% and 15.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.35, while the 7-day volatility ratio is showing 3.95% which for the 30-day chart, stands at 6.52%. Furthermore, Adma Biologics Inc (ADMA)’s beta value is 0.57, and its average true range (ATR) is 0.98.
A comparison of Adma Biologics Inc (ADMA) with its peers suggests the former has fared considerably weaker in the market. ADMA showed an intraday change of -2.57% in last session, and over the past year, it grew by 213.20%%.
Data on historical trading for Adma Biologics Inc (NASDAQ:ADMA) indicates that the trading volumes over the past 10 days have averaged 3.9 and over the past 3 months, they’ve averaged 2.68 million. According to company’s latest data on outstanding shares, there are 236.62 million shares outstanding.
Nearly 3.51% of Adma Biologics Inc’s shares belong to company insiders and institutional investors own 86.22% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.07 million shares as on 2025-03-14, resulting in a short ratio of 5.3. According to the data, the short interest in Adma Biologics Inc (ADMA) stood at 653.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 13.74 million. The stock has risen by 14.87% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADMA stock heading into the next quarter.
